Title: Cetuximab
CAS Registry Number: 205923-56-4
CAS Name: Anti-(human epidermal growth factor receptor) immunoglobulin G1 (human-mouse monoclonal C225 g1-chain), disulfide with human-mouse monoclonal C225 k-chain, dimer
Additional Names: C225
Manufacturers' Codes: IMC-C225
Trademarks: Erbitux (ImClone)
Literature References: Chimeric monoclonal antibody directed against human epithelial growth factor receptor (EGFR). Prepn: N. I. Goldstein et al., WO 9640210 (1995 to Imclone and MRC); eidem, Clin. Cancer Res. 1, 1311 (1995). Antitumor activity: J. Mendelson, ibid. 6, 747 (2000). Clinical pharmacokinetics: F. Robert et al., J. Clin. Oncol. 19, 3234 (2001); in combination with irinotecan: C. Delbaldo et al., Eur. J. Cancer 41, 1739 (2005). Clinical trial in head and neck cancer: B. Burtness et al., J. Clin. Oncol. 23, 8646 (2005); in combination with radiotherapy: J. A. Bonner et al., N. Engl. J. Med. 354, 567 (2006). Review of mechanism of action: R. S. Herbst et al., Expert Opin. Biol. Ther. 1, 719-732 (2001); J. Baselga, Eur. J. Cancer 37, S16-S22 (2001); of pharmacology and clinical studies: R. S. Herbst, C. J. Langer, Semin. Oncol. 29, Suppl. 4, 27-36 (2002); of use in colorectal cancer: S.-F. Wong, Clin. Ther. 27, 684-694 (2005).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies.
Cetyl Lactate Cetyl Palmitate Cetyldimethylethylammonium Bromide Cetylpyridinium Chloride Cevadine

Cetuximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target EGF receptor
Clinical data
Trade names Erbitux
AHFS/Drugs.com monograph
Licence data EMA:Link, US FDA:link
Legal status Prescription Only (S4) (AU) -only (CA) POM (UK) -only (US)
Routes intravenous
Pharmacokinetic data
Half-life 114 hrs
CAS number 205923-56-4 YesY
ATC code L01XC06
DrugBank DB00002
KEGG D03455 YesY
Chemical data
Formula C6484H10042N1732O2023S36 
Mol. mass 145781.6 g/mol
 N (what is this?)  (verify)

Cetuximab (Erbitux) is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is manufactured and distributed in the United States by the drug companies Bristol-Myers Squibb and Eli Lilly and Company and in Europe by the drug company Merck KGaA.

In July 2009, the FDA approved Erbitux for treatment of KRAS wild type colon cancer, since Cetuximab had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab)[1] This was the first genetic test to guide treatment of cancer.[2] In July 2012, the FDA approved a real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.[3]